<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Woods MW</submitter><funding>Canadian Institutes of Health Research</funding><pagination>27</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4021598</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Type I interferon (IFN) inhibits virus replication by activating multiple antiviral mechanisms and pathways. It has long been recognized that type I IFNs can potently block HIV-1 replication in vitro; as such, HIV-1 has been used as a system to identify and characterize IFN-induced antiviral proteins responsible for this block. IFN-induced HERC5 contains an amino-terminal Regulator of Chromosome Condensation 1 (RCC1)-like domain and a carboxyl-terminal Homologous to the E6-AP Carboxyl Terminus (HECT) domain. HERC5 is the main cellular E3 ligase that conjugates the IFN-induced protein ISG15 to proteins. This E3 ligase activity was previously shown to inhibit the replication of evolutionarily diverse viruses, including HIV-1. The contribution of the RCC1-like domain to the</pubmed_abstract><journal>Retrovirology</journal><pubmed_title>Interferon-induced HERC5 is evolving under positive selection and inhibits HIV-1 particle production by a novel mechanism targeting Rev/RRE-dependent RNA nuclear export.</pubmed_title><pmcid>PMC4021598</pmcid><funding_grant_id>MOP 130465</funding_grant_id><funding_grant_id>MOP 286719</funding_grant_id><funding_grant_id>MOP 317646</funding_grant_id><pubmed_authors>Haeryfar SM</pubmed_authors><pubmed_authors>Tom SK</pubmed_authors><pubmed_authors>Tong JG</pubmed_authors><pubmed_authors>Cavanagh PC</pubmed_authors><pubmed_authors>Woods MW</pubmed_authors><pubmed_authors>Szabo PA</pubmed_authors><pubmed_authors>Dikeakos JD</pubmed_authors><pubmed_authors>Barr SD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Interferon-induced HERC5 is evolving under positive selection and inhibits HIV-1 particle production by a novel mechanism targeting Rev/RRE-dependent RNA nuclear export.</name><description>&lt;h4>Background&lt;/h4>Type I interferon (IFN) inhibits virus replication by activating multiple antiviral mechanisms and pathways. It has long been recognized that type I IFNs can potently block HIV-1 replication in vitro; as such, HIV-1 has been used as a system to identify and characterize IFN-induced antiviral proteins responsible for this block. IFN-induced HERC5 contains an amino-terminal Regulator of Chromosome Condensation 1 (RCC1)-like domain and a carboxyl-terminal Homologous to the E6-AP Carboxyl Terminus (HECT) domain. HERC5 is the main cellular E3 ligase that conjugates the IFN-induced protein ISG15 to proteins. This E3 ligase activity was previously shown to inhibit the replication of evolutionarily diverse viruses, including HIV-1. The contribution of the RCC1-like domain to the</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Apr</publication><modification>2025-04-19T02:40:16.616Z</modification><creation>2019-03-27T01:28:15Z</creation></dates><accession>S-EPMC4021598</accession><cross_references><pubmed>24693865</pubmed><doi>10.1186/1742-4690-11-27</doi></cross_references></HashMap>